Opko Health, Inc.

OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company’s product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It offers its diagonostics and therapeutics that are used in the treatment of chronic kidney disease, obesity, asthma, chronic obstructive pulmonary disease (COPD), cancer and chemotherapy-induced nausea and vomiting, among others. It also offers neutraceuticals and veterinary products.The company also offers contract research services to other pharmaceutical companies. The company has its operational presence with its offices located in Chile, Mexico, Spain, Ireland, Canada and Israel. OPKO is headquartered in Miami, Florida, the US.The company reported revenues of (US Dollars) US$1,067.5 million for the fiscal year ended December 2017 (FY2017), a decrease of 12.6% over FY2016. The operating loss of the company was US$280.1 million in FY2017, compared to an operating loss of US$73.3 million in FY2016. The net loss of the company was US$308.9 million in FY2017, compared to a net loss of US$25.1 million in FY2016.The company reported revenues of US$263.7 million for the second quarter ended June 2018, an increase of 3.4% over the previous quarter. Company United States 4400 Biscayne Blvd Y http://www.opkorenal.com